Research News
The Impact of BMI on IP Therapy
(May 25, 2016) A new study published in the International Journal of Gynecological Cancer earlier this month investigated the impact of body mass index (BMI) on completion, complications, and clinical outcomes of intraperitoneal (IP) chemotherapy in…
Webinar: Clinical Trials: What you need to know
Oliver Dorigo, MD, PhD, Director of the Stanford Gynecologic Oncology Clinical Care Program and Director of Stanford Obstetrics and Gynecology’s Division of Gynecologic Oncology provided an introduction to clinical trials for ovarian cancer…
Long Term Survival Study Recruiting Participants
The Consortium for Long-Term Survival — is bringing together research groups worldwide…
OCRFA Research Helps Explain Resistance to Chemotherapy
(May 4, 2016) Research funded in part by an OCRFA research grant to Dr…
Irregular Periods May Increase Ovarian Cancer Risk
Research published last month in the International Journal of Cancer showed an unexpected finding: young women with irregular menstrual periods may be at higher risk of developing—and dying from—ovarian cancer later in life…
Irregular Periods May Increase Ovarian Cancer Risk
(May 2, 2016) Research published last month in the International Journal of Cancer showed an unexpected finding: young women with irregular menstrual periods may be at higher risk of developing—and dying from—ovarian cancer later in life…
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research
Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A…
Hormone Therapy Safe After Nonserous Ovarian Cancer
(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer…
Hormone Therapy Safe After Nonserous Ovarian Cancer
New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer…
OCRFA Statement on Results of GOG 252
Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer…
Research Update: Updated ICON6 Final Progression Free Survival analysis
The Lancet has recently published an update to the progression-free survival (PFS) data of theICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013…
Updated ICON6 Final Progression Free Survival analysis
(March 31, 2016) The Lancet has recently published an update to the progression-free survival (PFS) data of the ICON6 trial. (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013…